[go: up one dir, main page]

MX2015016893A - Combinacion de ro5503781 y capecitabina para la terapia para el cancer. - Google Patents

Combinacion de ro5503781 y capecitabina para la terapia para el cancer.

Info

Publication number
MX2015016893A
MX2015016893A MX2015016893A MX2015016893A MX2015016893A MX 2015016893 A MX2015016893 A MX 2015016893A MX 2015016893 A MX2015016893 A MX 2015016893A MX 2015016893 A MX2015016893 A MX 2015016893A MX 2015016893 A MX2015016893 A MX 2015016893A
Authority
MX
Mexico
Prior art keywords
capecitabine
combination
cancer therapy
product
component
Prior art date
Application number
MX2015016893A
Other languages
English (en)
Inventor
Brian Higgins
Gwen Nichols
Kathryn E Packman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015016893A publication Critical patent/MX2015016893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan productos farmacéuticos que comprenden a) un primer componente que comprende el compuesto de fórmula (ver Fórmula) (A); y b) un segundo componente que comprende capecitabina, para el tratamiento simultáneo o secuencial del cáncer, equipos que comprenden el producto, así como métodos para tratar a pacientes con cáncer, mediante la administración del producto.
MX2015016893A 2013-06-19 2014-06-16 Combinacion de ro5503781 y capecitabina para la terapia para el cancer. MX2015016893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361836894P 2013-06-19 2013-06-19
PCT/EP2014/062490 WO2014202492A1 (en) 2013-06-19 2014-06-16 Combination of ro5503781 and capecitabine for cancer therapy

Publications (1)

Publication Number Publication Date
MX2015016893A true MX2015016893A (es) 2016-04-07

Family

ID=50981495

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016893A MX2015016893A (es) 2013-06-19 2014-06-16 Combinacion de ro5503781 y capecitabina para la terapia para el cancer.

Country Status (14)

Country Link
US (1) US20160129033A1 (es)
EP (1) EP3010513B1 (es)
JP (1) JP6239745B2 (es)
KR (1) KR20160007662A (es)
CN (1) CN105307660A (es)
BR (1) BR112015029658A2 (es)
CA (1) CA2912816A1 (es)
ES (1) ES2741003T3 (es)
HK (1) HK1214502A1 (es)
MX (1) MX2015016893A (es)
PL (1) PL3010513T3 (es)
RU (1) RU2015152577A (es)
TR (1) TR201910701T4 (es)
WO (1) WO2014202492A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227932A1 (en) * 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US8232298B2 (en) * 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
CN101405281B (zh) * 2006-03-22 2013-12-11 詹森药业有限公司 Mdm2和p53相互作用的抑制剂
US8367699B2 (en) * 2006-09-15 2013-02-05 Nexuspharma, Inc. Tetrahydro-isoquinolines
JP5053674B2 (ja) * 2007-03-26 2012-10-17 テルモ株式会社 耳式体温計
KR101434009B1 (ko) * 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
CA2912816A1 (en) 2014-12-24
HK1214502A1 (zh) 2016-07-29
JP2016522228A (ja) 2016-07-28
CN105307660A (zh) 2016-02-03
RU2015152577A (ru) 2017-07-24
TR201910701T4 (tr) 2019-08-21
ES2741003T3 (es) 2020-02-07
EP3010513A1 (en) 2016-04-27
US20160129033A1 (en) 2016-05-12
PL3010513T3 (pl) 2019-11-29
WO2014202492A1 (en) 2014-12-24
KR20160007662A (ko) 2016-01-20
BR112015029658A2 (pt) 2017-07-25
EP3010513B1 (en) 2019-06-05
JP6239745B2 (ja) 2017-11-29

Similar Documents

Publication Publication Date Title
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
NZ629456A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
TW201613887A (en) Antiproliferative compounds and methods of use thereof
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX340090B (es) Analogos de spliceostatina.
PH12016502354A1 (en) Pharmaceutical composition
NZ730809A (en) Methods for treating filoviridae virus infections
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MY201080A (en) Nlrp3 modulators
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX2016009663A (es) Derivados de icariina.
PH12018501237A1 (en) Isoindole compounds